Cardiologia

Revisão | Considerações cardíacas no transplante hepático.

19 Fev, 2022 | 13:39h

Cardiac considerations in liver transplantation – Cleveland Clinic Journal of Medicine

Metanálise mostra que a prevalência geral de intolerância à estatina é de cerca de 9% e identifica os fatores de risco mais comuns.

17 Fev, 2022 | 15:31h

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Comentários:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Conteúdos relacionados:

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

Comentário no Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022

Revisão | Diagnóstico e tratamento de síndromes coronarianas agudas.

17 Fev, 2022 | 15:29h

Diagnosis and Treatment of Acute Coronary Syndromes: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Diagnosis and Treatment of Acute Coronary Syndromes – JAMA

Revisão | Tratamento transcateter para doença da valva tricúspide.

17 Fev, 2022 | 14:22h

Transcatheter treatment for tricuspid valve disease – EuroIntervention

Podcast | Perguntas e respostas mais frequentes sobre hipertensão: casos ambulatoriais comuns.

17 Fev, 2022 | 14:21h

#321 Hypertension FAQ: Common Outpatient Cases with Dr. Jordy Cohen – The Curbsiders

Revisão sistemática | Características eletrocardiográficas da disfunção diastólica de ventrículo esquerdo e da insuficiência cardíaca com fração de ejeção preservada.

15 Fev, 2022 | 11:34h

Electrocardiographic Features of Left Ventricular Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Systematic Review – Frontiers in Cardiovascular Medicine

M-A | Terapia antiplaquetária única deve ser usada após implante de válvula aórtica transcateter em pacientes sem indicação de anticoagulação.

15 Fev, 2022 | 11:16h

Comparing Single- and Dual-Antiplatelet Therapies After Transcatheter Aortic Valve Implantation – The Annals of Thoracic Surgery (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

M-A: Aspirin alone better than dual antiplatelet therapy after transcatheter aortic valve implantation

#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation

#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).

#AHA19 – [Abstract Only] Randomized Trial: An Antiplatelet-based Strategy is Associated with Better Outcomes vs. Anticoagulation After Transcatheter Aortic-Valve Replacement

Futilidade no implante de válvula aórtica transcateter: busca por clareza.

15 Fev, 2022 | 11:11h

Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity – Interventional Cardiology

Conteúdo relacionado: Predictors and clinical outcomes of poor symptomatic improvement after transcatheter aortic valve replacement – Editorial: Transcatheter aortic valve replacement: when should we say no?

Diretriz da OMS | Tratamento farmacológico da hipertensão em adultos.

14 Fev, 2022 | 16:02h

Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary – Hypertension

Estudo randomizado | Em pacientes com choque cardiogênico recebendo ECMO venoarterial, a hipotermia moderada não reduziu, de modo significativo, a mortalidade em 30 dias. No grupo de pacientes em hipotermia moderada, 42% morreram vs. 51% no grupo normotermia (OR ajustada, 0,71 [IC 95%, 0,45 a 1,13], P = 0,15).

14 Fev, 2022 | 15:56h

Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)

Comentário: Hypothermia vs. Normothermia for Cardiogenic Shock Patients on VA-ECMO – American College of Cardiology